Compare CHWY & SNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CHWY | SNN |
|---|---|---|
| Founded | 2010 | 1856 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Industrial Specialties |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.2B | 14.0B |
| IPO Year | 2019 | 1999 |
| Metric | CHWY | SNN |
|---|---|---|
| Price | $34.79 | $33.24 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 24 | 4 |
| Target Price | ★ $45.14 | $32.83 |
| AVG Volume (30 Days) | ★ 7.1M | 583.8K |
| Earning Date | 12-10-2025 | 10-30-2025 |
| Dividend Yield | N/A | ★ 2.20% |
| EPS Growth | N/A | ★ 59.91 |
| EPS | 0.35 | ★ 0.56 |
| Revenue | ★ $12,345,235,000.00 | $5,944,000,000.00 |
| Revenue This Year | $8.72 | $7.85 |
| Revenue Next Year | $7.87 | $5.43 |
| P/E Ratio | $99.54 | ★ $28.67 |
| Revenue Growth | ★ 9.17 | 5.35 |
| 52 Week Low | $29.83 | $23.69 |
| 52 Week High | $48.62 | $38.79 |
| Indicator | CHWY | SNN |
|---|---|---|
| Relative Strength Index (RSI) | 52.30 | 42.94 |
| Support Level | $31.16 | $31.95 |
| Resistance Level | $34.98 | $33.56 |
| Average True Range (ATR) | 1.31 | 0.40 |
| MACD | 0.24 | 0.10 |
| Stochastic Oscillator | 94.20 | 77.42 |
Chewy is the largest e-commerce petcare retailer in the US, generating $11.9 billion in fiscal 2024 sales across pet food, treats, hard goods, and pharmacy categories. The firm was founded in 2011, acquired by PetSmart in 2017, and tapped public markets as a stand-alone company in 2019 after spending a couple of years developing under the aegis of the pet superstore chain. The firm generates sales from pet food, treats, over-the-counter medications, medical prescription fulfillment, and hard goods like crates, leashes, and bowls.
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.